

Public Health Evidence Report Following Engagement Activity

This form is to be completed by the Policy Working Group's Public Health Lead if stakeholders identify potential new evidence during policy development engagement activities. The Public Health Lead will assess the evidence raised against the Population, Intervention, Comparator and Outcome (PICO) criteria and will record the studies in the appropriate boxes in the 'Outcome for studies suggested during engagement activities' section of this form. In cases where newly identified evidence has a material impact, please return the completed form to the Clinical Effectiveness Team (CET).

URN	2124
Policy title:	Siltuximab for Idiopathic Multicentric Castleman Disease
CRG:	Chemotherapy
NPOC:	Cancer
Engagement activity	Stakeholder testing
Date	22/12/2022

Description of comments during engagement (If studies have been suggested please provide a list of references)	<p>During stakeholder testing the following additional evidence was identified:</p> <ol style="list-style-type: none"> 1) Mukherjee S, Martin R, Yarlagadda S, et al. Epidemiology and Treatment Patterns of HHV-8-Negative/Idiopathic Multicentric Castleman Disease in the era of Interleukin-6 Directed Therapy. EHA. 2020. EP1275 2) Rossi, J.-F., Zinzani, P.L., Casper, C., Voorhees, P.M., Fayad, L., Kanhai, K., Kurzrock, R., and Rhee, F.V. (2022). Post hoc analysis of a long-term safety extension study: Responses to siltuximab in idiopathic multicentric Castleman disease patients receiving on-label dosing. Journal of Clinical Oncology 40,e19586-e19586. 10.1200/JCO.2022.40.16_suppl.e19586. file:///C:/Users/sbroy/AppData/Local/Temp/2/MicrosoftEdgeDownloads/a99cb746-b5a3-444a-b409-f05522e5a10e/jco.2022.40.16_suppl.e19586.pdf 3) Mukherjee S, Martin R, Sande B, et al. Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients. 62nd ASH Annual Meeting and Exposition. Virtual. 5–8 December 2020. 2059. 4) Frits van Rhee, Adam Rosenthal, Karan Kanhai, Rabecka Martin, Katherine Nishimura, Antje Hoering, David C. Fajgenbaum; Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease. Blood Adv 2022; 6 (16): 4773–4781. doi: https://doi.org/10.1182/bloodadvances.2022007112 5) Francis Shupo, Nicola Mason, Emily Jones, Grace Wayi-Wayi, Mileva Repasky, Matthew Franklin, John Brazier, Natasa Zibelnik, Sudipto
---	--

	<p>Mukherjee SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE AMONG PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) – FINDINGS FROM AN INTERNATIONAL IMCD PATIENT SURVEY EHA Library. Mukherjee S. 06/10/22; 357771; P911</p> <p>6) Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016; 3(4):e163-75.</p> <p>7) van Rhee F, Casper C, Voorhees PM, et al. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials. Lancet Haematol. 2020; 7(3):e209-e17.</p>
Action taken by Public Health lead	Review of the additional evidence against the PICO, Evidence Review and Policy Proposition.
Outcome for studies suggested during engagement activities	
1. Evidence already identified during the evidence review	<p>The following were identified and correctly excluded from the evidence review:</p> <p>6) Liu AY, Nabel CS, Finkelman BS, et al. <i>Idiopathic multicentric Castleman's disease: a systematic literature review</i>. Lancet Haematol. 2016; 3(4):e163-75.</p> <p>7) van Rhee F, Casper C, Voorhees PM, et al. <i>Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials</i>. Lancet Haematol. 2020; 7(3):e209-e17.</p>
2. New evidence identified by stakeholders that does not fall within PICO and search methodology	<p>1) Mukherjee S, Martin R, Yarlagadda S, et al. <i>Epidemiology and Treatment Patterns of HHV-8-Negative/Idiopathic Multicentric Castleman Disease in the era of Interleukin-6 Directed Therapy</i>. EHA. 2020. EP1275</p> <p>This evidence is a poster abstract and therefore does not meet the PICO/Evidence Review inclusion criteria.</p> <p>2) Rossi, J.-F., Zinzani, P.L., Casper, C., Voorhees, P.M., Fayad, L., Kanhai, K., Kurzrock, R., and Rhee, F.V. (2022). <i>Post hoc analysis of a long-term safety extension study: Responses to siltuximab in idiopathic multicentric Castleman disease patients receiving on-label dosing</i>. Journal of Clinical Oncology 40, e19586-e19586. 10.1200/JCO.2022.40.16_suppl.e19586.</p> <p>This evidence is a Meeting Abstract and therefore does not meet the PICO/Evidence Review inclusion criteria.</p> <p>3) Mukherjee S, Martin R, Sande B, et al. <i>Longitudinal Population Level Analysis of Healthcare Resource Utilization, Comorbidity, and Survival in Idiopathic Multicentric Castleman Disease Patients</i>. 62nd ASH Annual Meeting and Exposition. Virtual. 5–8 December 2020. 2059</p>

	<p>This evidence is a poster abstract and therefore does not meet the PICO/Evidence Review inclusion criteria.</p> <p>5) Francis Shupo, Nicola Mason, Emily Jones, Grace Wayi-Wayi, Mileva Repasky, Matthew Franklin, John Brazier, Natasa Zibelnik, Sudipto Mukherjee <u>SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE AMONG PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) – FINDINGS FROM AN INTERNATIONAL IMCD PATIENT SURVEY</u> EHA Library. Mukherjee S. 06/10/22; 357771; P911</p> <p>This evidence is a poster abstract and therefore does not meet the PICO/Evidence Review inclusion criteria.</p>
<p>3.New evidence identified by stakeholders that falls within PICO and search methodology but does not materially affect the conclusions of the existing evidence review</p>	<p>4) Frits van Rhee, Adam Rosenthal, Karan Kanhai, Rabecka Martin, Katherine Nishimura, Antje Hoering, David C. Fajgenbaum; <i>Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease</i>. Blood Adv 2022; 6 (16): 4773–4781. doi: https://doi.org/10.1182/bloodadvances.2022007112</p> <p>This evidence was published in August 2022 outside of the search dates of the evidence review (completed May 2022). However, it does meet the rest of the PICO criteria.</p> <p>The paper is an updated presentation of the cohort of 79 patients within <i>van Rhee F, Rossi JF, Simpson D, Fosså A, Dispenzieri A, Kuruvilla J, Goh YT, Cho SG, Capra M, Liu T, Casper C, Cavet J, Wong RS. Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab. British Journal of Haematology 2021, 192:e28-e31</i> that was included within the evidence review.</p> <p>Van Rhee (2022) does present extended estimates on progression free survival for siltuximab vs placebo (2 years compared with 14 months within the evidence review). However, it does <u>not</u> materially change the evidence review conclusions which found that <i>“The studies identified for this review therefore provide high to moderate evidence of better outcomes with siltuximab plus best supportive care than placebo plus best supportive care in adults with iMCD”</i>.</p>
<p>4.New evidence identified by stakeholders that falls within PICO and search methodology, that does materially affect the conclusions of the existing</p>	<p>None</p>

evidence review. Updated evidence review to be undertaken (to be agreed with CET)	
--	--

Completed by:	Public Health Consultant
Date:	04/01/2023

Peer reviewed and supported by:	N/A
Date:	N/A